Results 251 to 260 of about 74,894 (355)

Cost-effectiveness of sugemalimab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced oesophageal squamous cell carcinoma in China. [PDF]

BMJ Open
Yan C, Li Z, Li J, Huang R, Li S, Diao R.   +5 more
europepmc   +1 more source

Fiscal and Tax QA via Clause-Level Knowledge Graphs and Retrieval-augmented Large Language Models

Hao Chen, Xianglei Bu, Shupeng Tian
openalex   +1 more source

Cost‐effectiveness of in‐hospital motivational smoking cessation counselling and proactive referral to community‐based follow‐up

Addiction, EarlyView.
Abstract Background and aim In a randomised open‐label trial among hospitalised patients with atherosclerotic vascular disease, motivational smoking cessation counselling with proactive referral to community‐based follow‐up was more effective than brief cessation advice and written information, with 6‐month continuous abstinence rates of 49.5% vs. 24.5%
Karin Pleym, Ingrid Engebretsen, Elise Sverre, Toril Dammen, Einar Huseby, Mohpal Singh Kahlon, Marie Stugaard, Henrik Støvring, Ivar Sønbø Kristiansen, John Munkhaugen   +9 more
wiley   +1 more source

QALYs or short straws

BMJ, 1986
openaire   +5 more sources

Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer. [PDF]

Front Oncol
Li D, Zhao X, Jia H, Cui R, Cao A, Huo L.   +5 more
europepmc   +1 more source

A patient-specific QA comparison between 2D and 3D diode arrays for single-lesion SRS and SBRT treatments.

, 2021
Yongsook C. Lee, Yongbok Kim
openalex   +1 more source

Health and economic impact of universal screening and management of alcohol use disorders in India: An economic modelling study

Addiction, EarlyView.
Abstract Aim The study assessed the health and economic implications as well as the cost‐utility of implementing universal alcohol use disorder (AUD) screening in 15–74 years population at the primary healthcare level compared with the current practice of diagnosis and management of symptomatic AUD patients seeking formal healthcare. Design Model‐based
Neha Purohit, Shubhmohan Singh, Atul Ambekar, Ajay Duseja, Ashwani Kumar Mishra, Girish N. Rao, Kathirvel Soundappan, Atul Kotwal, Shankar Prinja   +8 more
wiley   +1 more source

Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country. [PDF]

PLoS One
Do TX, Nguyen HT, Nguyen PTL, Kieu MTT, Duong TV, Pham VNH.   +5 more
europepmc   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. [PDF]

Appl Health Econ Health Policy
Woudberg R, Sinanovic E.
europepmc   +1 more source